Artur Schmidtchen
Corporate Officer/Principal en University of Lund .
Perfil
Artur Schmidtchen is the founder of Sista versen 26366 AB, founded in 2009, and DermaGen AB, founded in 2004.
At DermaGen AB, he held the title of Director from 2004 to 2011.
Currently, Dr. Schmidtchen is a Professor at the University of Lund.
Cargos activos de Artur Schmidtchen
| Empresas | Cargo | Inicio |
|---|---|---|
| University of Lund | Corporate Officer/Principal | - |
Antiguos cargos conocidos de Artur Schmidtchen.
| Empresas | Cargo | Fin |
|---|---|---|
Sista versen 26366 AB
 Sista versen 26366 AB Pharmaceuticals: MajorHealth Technology Sista Versen 26366 AB discovers treatments for inflammatory disorders. Their treatment is based on properties of new classes of endogenous host defense peptides from proteins within the coagulation cascade, which display potent immune-modulating properties. The firm develops drugs that prevent sepsis development. The company was founded by Artur Schmidtchen and Nils Martin Malmsten on October 26, 2009 and is headquartered in Lund, Sweden. | Fundador | - |
DermaGen AB
 DermaGen AB Pharmaceuticals: MajorHealth Technology DermaGen AB develops drugs and medical devices. It focuses on the development of topically applied products for the prevention and treatment of bacterial and fungal skin infections. The company was founded on February 2, 2004 and is headquartered in Solna, Sweden. | Fundador | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
DermaGen AB
DermaGen AB Pharmaceuticals: MajorHealth Technology DermaGen AB develops drugs and medical devices. It focuses on the development of topically applied products for the prevention and treatment of bacterial and fungal skin infections. The company was founded on February 2, 2004 and is headquartered in Solna, Sweden. | Health Technology |
Sista versen 26366 AB
Sista versen 26366 AB Pharmaceuticals: MajorHealth Technology Sista Versen 26366 AB discovers treatments for inflammatory disorders. Their treatment is based on properties of new classes of endogenous host defense peptides from proteins within the coagulation cascade, which display potent immune-modulating properties. The firm develops drugs that prevent sepsis development. The company was founded by Artur Schmidtchen and Nils Martin Malmsten on October 26, 2009 and is headquartered in Lund, Sweden. | Health Technology |
- Bolsa de valores
- Insiders
- Artur Schmidtchen
